Skip to main content
SpringerLink
Log in

Update ESMO: gastric and esophageal cancer

  • original report
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

During this year’s virtual congress of the European Society of Oncology (ESMO) some practice-changing abstracts were presented. Especially immunotherapy (IO) has found its way into the treatment of esophageal (EC) and gastric cancer (GC) in both the adjuvant and palliative setting. The CheckMate 577 trial, which was presented in EMSO Presidential Symposium III, showed a doubling in disease-free survival (DFS) for patients with resected esophageal (EC) or esophagogastric junction cancer (EGJC) following neoadjuvant chemoradiation therapy (CRT), who had not achieved a pathological complete response, treated with nivolumab versus placebo. For advanced disease, the KEYNOTE-590 trial revealed a benefit of adding pembrolizumab to chemotherapy for patients with locally advanced or metastatic adenocarcinoma (EAC) or squamous cell carcinoma of the esophagus (ESCC) or EGJC Siewert type 1. In the CheckMate 649 study, patients (predominantly Caucasians) with advanced gastric, EGJC or EAC benefitted from the addition of nivolumab to chemotherapy in terms of overall survival (OS) and progression-free survival (PFS). In contrast, in the ATTRACTION‑4 trial, the Asian population gained a prolongation of PFS but not of OS by adding IO to chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Shah MA, Kennedy EB, Catenacci DV, Dana C, et al. Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline. J Clin Oncol. 2020;38:23:2677–94.

    Article  Google Scholar 

  2. Shapiro J, van Lanschot JJB, Hulshof MCCM. van Hagen et al. CROSS study group. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8.

    Article  Google Scholar 

  3. Kato K, Cho BCC, Takahashi M, Okada M, et al. Nivoluma versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refratory to prevoius chemotheraoy (Attraction-3). Lancet Oncol. 2019;20(11):1506–17.

    Article  CAS  Google Scholar 

  4. Kang YK, Boku N, Satoh T, Ryu MH, et al. Nivoluma in patients with advanced gastric or gastro-osophageal junction cancer refractory to, or intolerant of, at least two previous chemotheraoy regimes (Attraction-2). Lancet. 2017;390(10111):2461–71.

    Article  CAS  Google Scholar 

  5. Murphy MB, Xiao L, Patel VR, Maru DM, et al. Pathological complete response in patient with esophageal cancer after the trimodality approach: The associaton with baseline variables and survival. Cancer. 2017;123(21):4106–13.

    Article  Google Scholar 

  6. Njei B, McCarty TR, Birk JW. Trends in esophageal cancer survival in United States adults from 1973 to 2009: A SEER database analysis. J Gastroenterol Hepatol. 2016;31(6):1141–6.

    Article  Google Scholar 

  7. Kies MS, Rosen ST, Tsang TK, Shetty R, et al. Cisplatin and 5‑fluorouracil in the primary management of squamous esophageal cancer. Cancer. 1987;60(9):2156–60.

    Article  CAS  Google Scholar 

  8. Shah MA, Adenis A, Enzinger PC. Kojima T et al Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study. J Clin Oncol. 2019;37(no.15_suppl):4010–4010.

    Article  Google Scholar 

  9. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635–48.

    Article  CAS  Google Scholar 

  10. Fuch CS, Shitara K, Di Bartolomeo M, et al. Ramucirumab with cisplatin and flouropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL). Lancet Oncol. 2019;20(3):420–35.

    Article  Google Scholar 

  11. Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169–75.

    Article  Google Scholar 

  12. Al-Batran SE, Homann N, Schmalenberg H, Kopp HG, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO). J Clin Oncol. 2017;35(no15_suppl):4004–4004.

    Article  Google Scholar 

  13. Weber J, Mandela M, Del Vecchio HJ, Gogas HJ, et al. Adjuvant Nivolumab verus Ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Barmherzige Schwestern, Seilerstaette 4, 4020, Linz, Austria

    Ulrich Popper MD

  2. Gastrointestinal Cancer Center, Ordensklinikum Linz, Linz, Austria

    Holger Rumpold MD

  3. Medical Faculty, Johannes Kepler University, Linz, Austria

    Holger Rumpold MD

Authors
  1. Ulrich Popper MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Holger Rumpold MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrich Popper MD.

Ethics declarations

Conflict of interest

U. Popper and H. Rumpold declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Popper, U., Rumpold, H. Update ESMO: gastric and esophageal cancer. memo 14, 180–183 (2021). https://doi.org/10.1007/s12254-021-00694-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-021-00694-5

Keywords

Search

Navigation